Clinical Trials Logo

Filter by:
NCT ID: NCT03316898 Not yet recruiting - Alzheimer's Disease Clinical Trials

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

Start date: October 25, 2017
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the brain metabolic response using Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), safety, tolerability and pharmacokinetics of AGN-242071 in patients with mild to moderate Alzheimer's Disease on a stable dose of 10 mg donepezil with or without memantine standard of care.

NCT ID: NCT03316859 Recruiting - Constipation Clinical Trials

Naloxegol and Opioid-induced Constipation

Start date: October 23, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This is a double-blind, randomized, placebo-controlled trial to examine the effectiveness of adding one 25mg dose of naloxegol to the cardiac surgery pre-operative regimen.

NCT ID: NCT03316794 Not yet recruiting - Cancer - Breast Clinical Trials

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

Start date: November 13, 2017
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label study in participants with triple negative breast cancer (TNBC) to study the safety, tolerability, pharmacokinetics and preliminary efficacy of SC-005. This study consists of 2 parts: Part A (dose regimen finding) followed by Part B (dose expansion).

NCT ID: NCT03316599 Not yet recruiting - Pancreatic Cancer Clinical Trials

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Start date: November 30, 2017
Phase: Phase 1
Study type: Interventional

To identify the maximally tolerated dose of ficlatuzumab when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer.

NCT ID: NCT03316586 Not yet recruiting - Breast Cancer Clinical Trials

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

This research study is studying a combination of drugs as a possible treatment for metastatic triple-negative breast cancer. The drugs involved in this study are: - Cabozantinib (XL184) - Nivolumab

NCT ID: NCT03316573 Not yet recruiting - Lymphoma Clinical Trials

A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

This research study is studying a drug called pembrolizumab as a possible treatment for aggressive lymphoma or a histiocyte or dendritic cell neoplasm. The drug involved in this study is: -Pembrolizumab

NCT ID: NCT03316560 Not yet recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR-ORF15 Mutations

Start date: January 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing a human RPGR-ORF15 gene (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations. Approximately 15 participants will be enrolled and 3 dose levels will be evaluated in a dose-escalation format.

NCT ID: NCT03316547 Recruiting - Clinical trials for Premature Birth of Newborn

Supporting and Enhancing NICU Sensory Experiences (SENSE)

SENSE
Start date: October 2016
Phase: N/A
Study type: Interventional

Sixty-two preterm infants born less than or equal to 32 weeks gestation will be put into either the sensory-based intervention (experiment) group or traditional care (control) group. Consecutive admissions at St. Louis Children's Hospital (SLCH) who are hospitalized in a private NICU room will be recruited. The parents of infants in the sensory-based intervention group will be educated and supported by trained therapists to give different positive sensory experiences to their infants while hospitalized. The traditional care group with receive normal, standard care while hospitalized. For both care groups, infant neurobehavior, sensory processing, and parent mental health will be measured at term age prior to hospital discharge. Child development, sensory processing, and parent mental health will be measured again at age one year (corrected). Differences between the two groups will be explored.

NCT ID: NCT03316521 Recruiting - Clinical trials for Complement Mediated Diseases

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Start date: April 24, 2017
Phase: Phase 1
Study type: Interventional

Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the complement inhibitor AMY-101. A prospective, single-center, open-label, First-In-Human (FIH) clinical study in healthy male volunteers.

NCT ID: NCT03316456 Recruiting - Acute Leukemia Clinical Trials

Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction

Start date: August 22, 2017
Phase: N/A
Study type: Observational

This is an observational study to collect stool, blood, and urine from acute leukemia patients undergoing induction chemotherapy in order to generate preliminary data regarding the association between microbiota and chemotherapy-induced gut barrier damage. This study consists of inpatient collections of blood, urine, and stool while the patients are undergoing inpatient induction therapy. Patients will not be scheduled for any additional procedures or testing beyond what is required for clinical care.